Mundipharma announces a new commercial alliance
16 September 2015
Mundipharma has entered into a new License, Development and Commercialisation Agreement with Medical Developments International Limited, for Penthrox® (low dose methoxyflurane), as a self-inhaled analgesic for the treatment of emergency pain, in Europe.
“Mundipharma has a proud heritage in pain management and continually strives to advance new therapeutics in this space. With this alliance we are excited to expand our portfolio into the field of emergency pain relief and we look forward to quickly advancing the European development, registration and commercialisation of Penthrox® to maximise its success. We are delighted about the opportunity to work with Medical Developments International and the prospect for growth that this collaboration brings”, commented Kate Hurtig, Head of Pain at Mundipharma International.